

# $\Delta$ FosB: A sustained molecular switch for addiction

Eric J. Nestler\*, Michel Barrot, and David W. Self

Department of Psychiatry and Center for Basic Neuroscience, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9070

The longevity of some of the behavioral abnormalities that characterize drug addiction has suggested that regulation of neural gene expression may be involved in the process by which drugs of abuse cause a state of addiction. Increasing evidence suggests that the transcription factor  $\Delta$ FosB represents one mechanism by which drugs of abuse produce relatively stable changes in the brain that contribute to the addiction phenotype.  $\Delta$ FosB, a member of the Fos family of transcription factors, accumulates within a subset of neurons of the nucleus accumbens and dorsal striatum (brain regions important for addiction) after repeated administration of many kinds of drugs of abuse. Similar accumulation of  $\Delta$ FosB occurs after compulsive running, which suggests that  $\Delta$ FosB may accumulate in response to many types of compulsive behaviors. Importantly,  $\Delta$ FosB persists in neurons for relatively long periods of time because of its extraordinary stability. Therefore,  $\Delta$ FosB represents a molecular mechanism that could initiate and then sustain changes in gene expression that persist long after drug exposure ceases. Studies in inducible transgenic mice that overexpress either  $\Delta$ FosB or a dominant negative inhibitor of the protein provide direct evidence that  $\Delta$ FosB causes increased sensitivity to the behavioral effects of drugs of abuse and, possibly, increased drug seeking behavior. This work supports the view that  $\Delta$ FosB functions as a type of sustained "molecular switch" that gradually converts acute drug responses into relatively stable adaptations that contribute to the long-term neural and behavioral plasticity that underlies addiction.

Addiction research is focused on understanding the complex ways in which drugs of abuse change the brain to cause behavioral abnormalities that characterize addiction. One of the critical challenges in the field is to identify relatively stable drug-induced changes in the brain to account for those behavioral abnormalities that are particularly long-lived. For example, a human addict may be at increased risk for relapse even after years of abstinence.

The stability of these behavioral abnormalities has led to the suggestion that they may be mediated, at least in part, through changes in gene expression (1–3). According to this view, repeated exposure to a drug of abuse repeatedly perturbs transmission at particular synapses in the brain that are sensitive to the drug. Such perturbations eventually signal via intracellular messenger cascades to the nucleus, where they first initiate and then maintain changes in the expression of specific genes. A primary mechanism through which signal transduction pathways influence gene expression is the regulation of transcription factors, proteins that bind to regulatory regions of genes and modify their transcription.

One goal of addiction research, therefore, has been to identify transcription factors that are altered in brain regions implicated in addiction after chronic administration of drugs of abuse. Several such transcription factors have been identified over the past decade (1–6). The focus of this review is on one particular transcription factor called  $\Delta$ FosB.

## Induction of $\Delta$ FosB by Drugs of Abuse

$\Delta$ FosB, encoded by the *fosB* gene, is a member of the Fos family of transcription factors, which also include c-Fos, FosB, Fra1,

and Fra2 (7). These Fos family proteins heterodimerize with Jun family proteins (c-Jun, JunB, or JunD) to form active AP-1 (activator protein-1) transcription factors that bind to AP-1 sites (consensus sequence: TGAC/GTCA) present in the promoters of certain genes to regulate their transcription.

These Fos family proteins are induced rapidly and transiently in specific brain regions after acute administration of many drugs of abuse (Fig. 1) (8–11). Prominent regions are the nucleus accumbens and dorsal striatum, which are important mediators of behavioral responses to the drugs, in particular, their rewarding and locomotor-activating effects (12, 13). These proteins return to basal levels within hours of drug administration.

Very different responses are seen after chronic administration of drugs of abuse (Fig. 1). Biochemically modified isoforms of  $\Delta$ FosB (molecular mass 35–37 kDa) accumulate within the same brain regions after repeated drug exposure, whereas all other Fos family members show tolerance (that is, reduced induction compared with initial drug exposures). Such accumulation of  $\Delta$ FosB has been observed for cocaine, morphine, amphetamine, alcohol, nicotine, and phencyclidine (11, 14–18). There is some evidence that this induction is selective for the dynorphin/substance P-containing subset of medium spiny neurons located in these brain regions (15, 17), although more work is needed to establish this with certainty. The 35- to 37-kDa isoforms of  $\Delta$ FosB dimerize predominantly with JunD to form an active and long-lasting AP-1 complex within these brain regions (19, 20). These  $\Delta$ FosB isoforms accumulate with chronic drug exposure because of their extraordinarily long half-lives (21), and therefore persist in the neurons for at least several weeks after cessation of drug administration. It is interesting to note that these  $\Delta$ FosB isoforms are highly stable products of an immediate early gene (*fosB*). The stability of the  $\Delta$ FosB isoforms provides a novel molecular mechanism by which drug-induced changes in gene expression can persist despite relatively long periods of drug withdrawal.


Although the nucleus accumbens plays a critical role in the rewarding effects of drugs of abuse, it is believed to function normally by regulating responses to natural reinforcers, such as food, drink, sex, and social interactions (12, 13). As a result, there is considerable interest in a possible role of this brain region in other compulsive behaviors (e.g., pathological overeating, gambling, exercise, etc.). For this reason, we examined whether  $\Delta$ FosB is regulated in an animal model of compulsive running. Indeed, the stable 35- to 37-kDa isoforms of  $\Delta$ FosB are induced selectively within the nucleus accumbens in rats that show compulsive running behavior.<sup>†</sup>

This paper was presented at the Inaugural Arthur M. Sackler Colloquium of the National Academy of Sciences, "Neural Signaling," held February 15–17, 2001, at the National Academy of Sciences in Washington, DC.

Abbreviations: AP-1, activator protein-1; AMPA,  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; CREB, cAMP response element binding protein; Cdk5, cyclin-dependent kinase-5.

\*To whom reprint requests should be addressed. E-mail: eric.nestler@utsouthwestern.edu.

<sup>†</sup>Werme, M., Nestler, E. J. & Brene, S. (2001) *Soc. Neurosci. Abstr.*, in press.



**Fig. 1.** Scheme showing the gradual accumulation of  $\Delta$ FosB versus the rapid and transient induction of other Fos family proteins in response to drugs of abuse. (A) The autoradiogram illustrates the differential induction of these various proteins by acute stimulation (1–2 hr after a single drug exposure) versus chronic stimulation (1 day after repeated drug exposure). (B) Several waves of Fos-like proteins [comprised of c-Fos (52- to 58-kDa isoforms), FosB (46- to 50-kDa isoforms),  $\Delta$ FosB (33-kDa isoform), and Fra1 or Fra2 (40 kDa)] are induced in nucleus accumbens and dorsal striatal neurons by acute administration of a drug of abuse. Also induced are biochemically modified isoforms of  $\Delta$ FosB (35–37 kDa); they, too, are induced (although at low levels) after acute drug administration, but persist in brain for long periods because of their stability. (C) With repeated (e.g., twice daily) drug administration, each acute stimulus induces a low level of the stable  $\Delta$ FosB isoforms, which is indicated by the lower set of overlapping lines that indicate  $\Delta$ FosB induced by each acute stimulus. The result is a gradual increase in the total levels of  $\Delta$ FosB with repeated stimuli during a course of chronic treatment, which is indicated by the increasing stepped line in the graph.

**Biochemical Identity of Stable  $\Delta$ FosB Isoforms**

As mentioned above, the  $\Delta$ FosB isoforms that accumulate after chronic administration of a drug of abuse or compulsive running show a molecular mass of 35–37 kDa. They can be differentiated

**Table 1. Behavioral plasticity mediated by  $\Delta$ FosB in nucleus accumbens-dorsal striatum**

Increased locomotor activation in response to acute and repeated cocaine administration.
Increased rewarding responses to cocaine and morphine in place-conditioning assays.
Increased self-administration of low doses of cocaine.
Increased motivation for cocaine in progressive ratio assays.
Increased anxiolytic responses to alcohol.
Increased compulsive running behavior.

Based on data in refs. 28 and 29.<sup>†‡§¶</sup>

from the 33-kDa isoform of  $\Delta$ FosB that is induced rapidly but transiently after a single drug exposure (Fig. 1) (14, 19, 22). Current evidence suggests that the 33-kDa isoform is the native form of the protein, which is altered to form the more stable 35- to 37-kDa products (19, 21). However, the nature of the biochemical modification that converts the unstable 33-kDa isoform into the stable 35- to 37-kDa isoforms has remained obscure. It has been speculated that phosphorylation may be responsible (11). For example, induction of  $\Delta$ FosB is attenuated in mice lacking DARPP-32, a striatal-enriched protein (23, 24). Because DARPP-32 regulates the catalytic activity of protein phosphatase-1 and protein kinase A (25, 26), the requirement for this protein for the normal accumulation of the stable  $\Delta$ FosB isoforms suggests a possible role for phosphorylation in generation of these stable products.

**Role of  $\Delta$ FosB in Behavioral Plasticity to Drugs of Abuse**

Insight into the role of  $\Delta$ FosB in drug addiction has come largely from the study of transgenic mice in which  $\Delta$ FosB can be induced selectively within the nucleus accumbens and other striatal regions of adult animals (27, 28). Importantly, these mice overexpress  $\Delta$ FosB selectively in the dynorphin/substance P-containing medium spiny neurons, where the drugs are believed to induce the protein. The behavioral phenotype of the  $\Delta$ FosB-overexpressing mice, which in many ways resembles animals after chronic drug exposure, is summarized in Table 1. The mice show augmented locomotor responses to cocaine after acute and chronic administration (28). They also show enhanced sensitivity to the rewarding effects of cocaine and morphine in place-conditioning assays (11, 28) and will self-administer lower doses of cocaine than littermates that do not overexpress  $\Delta$ FosB.<sup>‡</sup> In contrast, these animals show normal conditioned locomotor sensitization to cocaine and normal spatial learning in the Morris water maze (28). These data indicate that  $\Delta$ FosB increases an animal’s sensitivity to cocaine and perhaps other drugs of abuse and may represent a mechanism for relatively prolonged sensitization to the drugs.

In addition, there is preliminary evidence that the effects of  $\Delta$ FosB may extend well beyond a regulation of drug sensitivity *per se* to more complex behaviors related to the addiction process. Mice expressing  $\Delta$ FosB work harder to self-administer cocaine in progressive ratio self-administration assays, suggesting that  $\Delta$ FosB may sensitize animals to the incentive motivational properties of cocaine and thereby lead to a propensity for relapse after drug withdrawal.<sup>‡</sup>  $\Delta$ FosB-expressing mice also show enhanced anxiolytic effects of alcohol,<sup>§</sup> a phenotype that has been associated with increased alcohol intake in humans.

<sup>†</sup>Whisler, K., Kelz, M. B., Chen, J. S., Nestler, E. J. & Self, D. W. (1999) *Soc. Neurosci. Abstr.* 25, 811.

<sup>‡</sup>Roberts, A., Picetti, R., Nestler, E. J., Koob, G. F. (2001) *Soc. Neurosci. Abstr.*, in press.

<sup>¶</sup>Peakman, M.-C., Colby, C., Duman, R. S., Allen, M. R., Stock, J. L., McNeish, J. D., Kelz, M. B., Chen, J. S., Nestler, E. J. & Schaeffer, E. (2000) *Soc. Neurosci. Abstr.* 26, 124.

Together, these early findings suggest that  $\Delta$ FosB, in addition to increasing sensitivity to drugs of abuse, produces qualitative changes in behavior that promote drug-seeking behavior. Thus,  $\Delta$ FosB may function as a sustained “molecular switch” that helps initiate and then maintain crucial aspects of the addicted state. An important question under current investigation is whether  $\Delta$ FosB accumulation during drug exposure promotes drug-seeking behavior after extended withdrawal periods, even after  $\Delta$ FosB levels have normalized (see below).

Adult mice that overexpress  $\Delta$ FosB selectively within the nucleus accumbens and dorsal striatum also exhibit greater compulsive running compared with control littermates.<sup>†</sup> These observations raise the interesting possibility that  $\Delta$ FosB accumulation within these neurons serves a more general role in the formation and maintenance of habit memories and compulsive behaviors, perhaps by reinforcing the efficacy of neural circuits in which those neurons function.


$\Delta$ FosB accumulates in certain brain regions outside the nucleus accumbens and dorsal striatum after chronic exposure to cocaine. Prominent among these regions are the amygdala and medial prefrontal cortex (15). A major goal of current research is to understand the contributions of  $\Delta$ FosB induction in these regions to the addiction phenotype.

Earlier work on *fosB* knockout mice revealed that these animals fail to develop sensitization to the locomotor effects of cocaine, which is consistent with the findings of the  $\Delta$ FosB-overexpressing mice mentioned above (22). However, the *fosB* mutants showed enhanced sensitivity to cocaine’s acute effects, which is inconsistent with these other findings. Interpretation of findings with the *fosB* mutants, though, is complicated by the fact that these animals lack not only  $\Delta$ FosB, but full-length FosB as well. Moreover, the mutants lack both proteins throughout the brain and from the earliest stages of development. Indeed, more recent work supports conclusions from the  $\Delta$ FosB overexpressing mice: inducible overexpression of a truncated mutant of c-Jun, which acts as a dominant negative antagonist of  $\Delta$ FosB, selectively in nucleus accumbens and dorsal striatum shows reduced sensitivity to the rewarding effects of cocaine.<sup>‡</sup> These findings emphasize the caution that must be used in interpreting results from mice with constitutive mutations and illustrate the importance of mice with inducible and cell type-specific mutations in studies of plasticity in the adult brain.

### Target Genes for $\Delta$ FosB

Because  $\Delta$ FosB is a transcription factor, presumably the protein causes behavioral plasticity through alterations in the expression of other genes.  $\Delta$ FosB is generated by alternative splicing of the *fosB* gene and lacks a portion of the C-terminal transactivation domain present in full-length FosB. As a result, it was originally proposed that  $\Delta$ FosB functions as a transcriptional repressor (29). However, work in cell culture has demonstrated clearly that  $\Delta$ FosB can either induce or repress AP-1-mediated transcription depending on the particular AP-1 site used (21, 29–31). Full-length FosB exerts the same effects as  $\Delta$ FosB on certain promoter fragments, but different effects on others. Further work is needed to understand the mechanisms underlying these varied actions of  $\Delta$ FosB and FosB.

Our group has used two approaches to identify target genes for  $\Delta$ FosB. One is the candidate gene approach. We initially considered  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors as putative targets, given the important role of glutamatergic transmission in the nucleus accumbens. Work to date has indicated that one particular AMPA glutamate receptor subunit, GluR2, may be a bona fide target for  $\Delta$ FosB (Fig. 2). GluR2 expression, but not the expression of other AMPA receptor subunits, is increased in nucleus accumbens (but not dorsal striatum) upon overexpression of  $\Delta$ FosB (28), and expression of a dominant negative




**Fig. 2.** The AMPA glutamate receptor subunit, GluR2, is a putative target for  $\Delta$ FosB. Shown is how  $\Delta$ FosB-mediated induction of GluR2 may alter the physiological responsiveness of nucleus accumbens neurons and lead to sensitized responses to drugs of abuse. According to this scheme, drugs of abuse produce their acute reinforcing effects via inhibition of nucleus accumbens neurons. With repeated exposure, the drugs induce  $\Delta$ FosB, which regulates numerous target genes, including GluR2. This increases the proportion of AMPA receptors (AMPA-R) on nucleus accumbens neurons that contain the GluR2 subunit, which causes reduced overall AMPA current and reduced Ca<sup>2+</sup> current. This reduced excitability could render the neurons more sensitive to the acute inhibitory effects of the drugs and thereby to the drugs’ reinforcing effects.

mutant attenuates the ability of cocaine to induce the protein.<sup>¶</sup> In addition, the promoter of the GluR2 gene contains a consensus AP-1 site that binds  $\Delta$ FosB (28). Overexpression of GluR2 in the nucleus accumbens, by use of viral-mediated gene transfer, increases an animal’s sensitivity to the rewarding effects of cocaine, thereby mimicking part of the phenotype seen in the  $\Delta$ FosB-expressing mice (28). Induction of GluR2 could account for the reduced electrophysiological sensitivity of nucleus accumbens neurons to AMPA receptor agonists after chronic cocaine administration (32), because AMPA receptors containing GluR2 show reduced overall conductance and reduced Ca<sup>2+</sup> permeability. Reduced responsiveness of these neurons to excitatory inputs may then enhance responses to a drug of abuse. However, the ways in which dopaminergic and glutamatergic signals in nucleus accumbens regulate addictive behavior remain unknown; this will require a neural circuit level of understanding, which is not yet available.

Another putative target for  $\Delta$ FosB is the gene encoding dynorphin. As stated earlier, dynorphin is expressed in the subset of nucleus accumbens medium spiny neurons that show induction of  $\Delta$ FosB. Dynorphin appears to function in an intercellular feedback loop: its release inhibits the dopaminergic neurons that innervate the medium spiny neurons, via  $\kappa$  opioid receptors present on dopaminergic nerve terminals in the nucleus accumbens and also on cell bodies and dendrites in the ventral tegmental area (Fig. 3) (33–35). This idea is consistent with the ability of a  $\kappa$  receptor agonist, upon administration into either of these two brain regions, to decrease drug reward (35). Recent work has indicated that  $\Delta$ FosB decreases the expression of dynorphin,<sup>||</sup> which could contribute to the enhancement of reward mechanisms seen with  $\Delta$ FosB induction. Interestingly, another drug-regulated transcription factor, CREB (cAMP response element binding protein) (2, 3), exerts the opposite

<sup>¶</sup>Shaw, T. Z., Gilden, L., Kelz, M., Chen, J. & Nestler, E. J. (2000) *Soc. Neurosci. Abstr.* 26, 525.




**Fig. 3.** Dynorphin is a putative target for  $\Delta$ FosB. Shown is a ventral tegmental area (VTA) dopamine (DA) neuron innervating a class of nucleus accumbens (NAc) GABAergic projection neuron that expresses dynorphin (DYN). Dynorphin serves a feedback mechanism in this circuit: dynorphin, released from terminals of the NAc neurons, acts on  $\kappa$  opioid receptors located on nerve terminals and cell bodies of the DA neurons to inhibit their functioning.  $\Delta$ FosB, by inhibiting dynorphin expression, may down-regulate this feedback loop and enhance the rewarding properties of drugs of abuse. Not shown is the reciprocal effect of CREB on this system: CREB enhances dynorphin expression and thereby attenuates the rewarding properties of drugs of abuse (4). GABA,  $\gamma$ -aminobutyric acid; DR, dopamine receptor; OR, opioid receptor.

effect: it induces dynorphin expression in the nucleus accumbens and reduces the rewarding properties of cocaine and morphine (4).\*\* Because drug-induced activation of CREB dissipates rapidly after drug administration, such reciprocal regulation of dynorphin by CREB and  $\Delta$ FosB could explain the reciprocal behavioral changes that occur during early and late phases of withdrawal, with negative emotional symptoms and reduced drug sensitivity predominating during early phases of withdrawal, and sensitization to the rewarding and incentive motivational effects of drugs predominating at later time points.

The second approach used to identify target genes for  $\Delta$ FosB involves DNA microarray analysis. Inducible overexpression of  $\Delta$ FosB increases or decreases the expression of numerous genes in the nucleus accumbens (36). Although considerable work is now needed to validate each of these genes as physiologic targets of  $\Delta$ FosB and to understand their contribution to the addiction phenotype, one important target appears to be Cdk5 (cyclin-dependent kinase-5). Thus, Cdk5 was initially identified as  $\Delta$ FosB-regulated by use of microarrays, and later shown to be induced in nucleus accumbens and dorsal striatum after chronic cocaine administration (37).  $\Delta$ FosB activates the *cdk5* gene via an AP-1 site present within the gene's promoter (36). Together, these data support a scheme wherein cocaine induces Cdk5 expression in these brain regions via  $\Delta$ FosB. Induction of Cdk5 appears to alter dopaminergic signaling at least in part via increased phosphorylation of DARPP-32 (37), which is converted from an inhibitor of protein phosphatase-1 to an inhibitor of protein kinase A upon its phosphorylation by Cdk5 (26).

### Role of $\Delta$ FosB in Mediating "Permanent" Plasticity to Drugs of Abuse

Although the  $\Delta$ FosB signal is relatively long-lived, it is not permanent.  $\Delta$ FosB degrades gradually and can no longer be detected in brain after 1–2 months of drug withdrawal, even though certain behavioral abnormalities persist for much longer periods of time. Therefore,  $\Delta$ FosB *per se* would not appear to be able to mediate these semipermanent behavioral abnormalities.



**Fig. 4.** Regulation of dendritic structure by drugs of abuse. Shown is the expansion of a neuron's dendritic tree after chronic exposure to a drug of abuse, as has been observed with cocaine in the nucleus accumbens and prefrontal cortex (41). The areas of magnification show an increase in dendritic spines, which is postulated to occur in conjunction with activated nerve terminals. This increase in dendritic spine density may be mediated via  $\Delta$ FosB and the consequent induction of Cdk5 (see text). Such alterations in dendritic structure, which are similar to those observed in some learning models (e.g., long-term potentiation), could mediate long-lived sensitized responses to drugs of abuse or environmental cues. [Reproduced with permission from ref. 3 (Copyright 2001, Macmillan Magazines Ltd.).]

The difficulty in finding the molecular adaptations that underlie the extremely stable behavioral changes associated with addiction is analogous to the challenges faced in the learning and memory field. Although there are elegant cellular and molecular models of learning and memory, it has not to date been possible to identify molecular and cellular adaptations that are sufficiently long-lived to account for highly stable behavioral memories. Indeed,  $\Delta$ FosB is the longest-lived adaptation known to occur in adult brain, not only in response to drugs of abuse, but to any other perturbation (that doesn't involve lesions) as well. Two proposals have evolved, both in the addiction and learning and memory fields, to account for this discrepancy.

One possibility is that more transient changes in gene expression, such as those mediated via  $\Delta$ FosB or other transcription factors (e.g., CREB), may mediate more long-lived changes in neuronal morphology and synaptic structure. For example, an increase in the density of dendritic spines (particularly an increase in two-headed spines) accompanies the increased efficacy of glutamatergic synapses at hippocampal pyramidal neurons during long-term potentiation (38–40), and parallels the enhanced behavioral sensitivity to cocaine mediated at the level of medium spiny neurons of the nucleus accumbens (41). It is not known whether such structural changes are sufficiently long-lived to account for highly stable changes in behavior, although the latter persist for at least 1 month of drug withdrawal. Recent evidence raises the possibility that  $\Delta$ FosB, and its induction of Cdk5, is one mediator of drug-induced changes in synaptic structure in the nucleus accumbens (Fig. 4).<sup>††</sup> Thus, infusion of a Cdk5 inhibitor into the nucleus accumbens prevents the ability of repeated cocaine exposure to increase dendritic spine density in this region. This is consistent with the view that Cdk5, which is enriched in brain, regulates neural structure and growth (see refs. 36 and 37). It is possible, although by no means proven, that such changes in neuronal morphology may outlast the  $\Delta$ FosB signal itself.

\*\*Barrot, M., Olivier, J. D. A., Zachariou, V., Neve, R. L. & Nestler, E. J. (2000) *Soc. Neurosci. Abstr.* 26, 485.

<sup>††</sup>Norrholm, S. D., Bibb, J. A., Nestler, E. J., Ouimet, C. C., Taylor, J. R. & Greengard, P. (2001) *Soc. Neurosci. Abstr.*, in press.

Another possibility is that the transient induction of a transcription factor (e.g.,  $\Delta$ FosB, CREB) leads to more permanent changes in gene expression through the modification of chromatin. These and many other transcription factors are believed to activate or repress the transcription of a target gene by promoting the acetylation or deacetylation, respectively, of histones in the vicinity of the gene (42). Although such acetylation and deacetylation of histones can apparently occur very rapidly, it is possible that  $\Delta$ FosB or CREB might produce longer-lasting adaptations in the enzymatic machinery that controls histone acetylation.  $\Delta$ FosB or CREB may also promote

longer-lived changes in gene expression by regulating other modifications of chromatin (e.g., DNA or histone methylation) that have been implicated in the permanent changes in gene transcription that occur during development (see refs. 42 and 43). Although these possibilities remain speculative, they could provide a mechanism by which transient adaptations to a drug of abuse (or some other perturbation) lead to essentially life-long behavioral consequences.

This work was supported by grants from the National Institute on Drug Abuse.

1. Nestler, E. J., Hope, B. T. & Widnell, K. L. (1993) *Neuron* **11**, 995–1006.
2. Berke, J. D. & Hyman, S. E. (2000) *Neuron* **25**, 515–532.
3. Nestler, E. J. (2001) *Nat. Rev. Neurosci.* **2**, 119–128.
4. Carlezon, W. A., Jr., Thome, J., Olson, V. G., Lane-Ladd, S. B., Brodtkin, E. S., Hiroi, N., Duman, R. S., Neve, R. L. & Nestler, E. J. (1998) *Science* **282**, 2272–2275.
5. O'Donovan, K. J., Tourtellotte, W. G., Millbrandt, J. & Baraban, J. M. (1999) *Trends Neurosci.* **22**, 167–173.
6. Mackler, S. A., Korutla, L., Cha, X. Y., Koebe, M. J., Fournier, K. M., Bowers, M. S. & Kalivas, P. W. (2000) *J. Neurosci.* **20**, 6210–6217.
7. Morgan, J. I. & Curran, T. (1995) *Trends Neurosci.* **18**, 66–67.
8. Young, S. T., Porrino, L. J. & Iadarola, M. J. (1991) *Proc. Natl. Acad. Sci. USA* **88**, 1291–1295.
9. Graybiel, A. M., Moratalla, R. & Robertson, H. A. (1990) *Proc. Natl. Acad. Sci. USA* **87**, 6912–6916.
10. Hope, B., Kosofsky, B., Hyman, S. E. & Nestler, E. J. (1992) *Proc. Natl. Acad. Sci. USA* **89**, 5764–5768.
11. Kelz, M. B. & Nestler, E. J. (2000) *Curr. Opin. Neurol.* **13**, 715–720.
12. Koob, G. F., Sanna, P. P. & Bloom, F. E. (1998) *Neuron* **21**, 467–476.
13. Wise, R. A. (1998) *Drug Alcohol Dependence* **51**, 13–22.
14. Hope, B. T., Nye, H. E., Kelz, M. B., Self, D. W., Iadarola, M. J., Nakabeppu, Y., Duman, R. S. & Nestler, E. J. (1994) *Neuron* **13**, 1235–1244.
15. Nye, H., Hope, B. T., Kelz, M., Iadarola, M. & Nestler, E. J. (1995) *J. Pharmacol. Exp. Ther.* **275**, 1671–1680.
16. Nye, H. E. & Nestler, E. J. (1996) *Mol. Pharmacol.* **49**, 636–645.
17. Moratalla, R., Elibol, B., Vallejo, M. & Graybiel, A. M. (1996) *Neuron* **17**, 147–156.
18. Pich, E. M., Pagliusi, S. R., Tessari, M., Talabot-Ayer, D., Hooft van Huijsduijnen, R. & Chiamulera, C. (1997) *Science* **275**, 83–86.
19. Chen, J. S., Nye, H. E., Kelz, M. B., Hiroi, N., Nakabeppu, Y., Hope, B. T. & Nestler, E. J. (1995) *Mol. Pharmacol.* **48**, 880–889.
20. Hiroi, N., Brown, J., Ye, H., Saudou, F., Vaidya, V. A., Duman, R. S., Greenberg, M. E. & Nestler, E. J. (1998) *J. Neurosci.* **18**, 6952–6962.
21. Chen, J., Kelz, M. B., Hope, B. T., Nakabeppu, Y. & Nestler, E. J. (1997) *J. Neurosci.* **17**, 4933–4941.
22. Hiroi, N., Brown, J., Haile, C., Ye, H., Greenberg, M. E. & Nestler, E. J. (1997) *Proc. Natl. Acad. Sci. USA* **94**, 10397–10402.
23. Fienberg, A. A., Hiroi, N., Mermelstein, P., Song, W.-J., Snyder, G. L., Nishi, A., Cheryan, A., O'Callaghan, J. P., Miller, D., Cole, D. G., et al. (1998) *Science* **281**, 838–842.
24. Hiroi, N., Feinberg, A., Haile, C., Greengard, P. & Nestler, E. J. (1999) *Eur. J. Neurosci.* **11**, 1114–1118.
25. Greengard, P., Allen, P. B. & Nairn, A. C. (1999) *Neuron* **23**, 435–447.
26. Bibb, J. A., Snyder, G. L., Nishi, A., Yan, Z., Meijer, L., Fienberg, A. A., Tsai, L. H., Kwon, Y. T., Girault, J. A., Czernik, A. J., et al. (1999) *Nature (London)* **402**, 669–671.
27. Chen, J. S., Kelz, M. B., Zeng, G. Q., Sakai, N., Steffen, C., Shockett, P. E., Picciotto, M., Duman, R. S. & Nestler, E. J. (1998) *Mol. Pharmacol.* **54**, 495–503.
28. Kelz, M. B., Chen, J. S., Carlezon, W. A., Whisler, K., Gilden, L., Beckmann, A. M., Steffen, C., Zhang, Y.-J., Marotti, L., Self, S. W., et al. (1999) *Nature (London)* **401**, 272–276.
29. Dobrazanski, P., Noguchi, T., Kovary, K., Rizzo, C. A., Lazo, P. S. & Bravo, R. (1991) *Mol. Cell Biol.* **11**, 5470–5478.
30. Nakabeppu, Y. & Nathans, D. (1991) *Cell* **64**, 751–759.
31. Yen, J., Wisdom, R. M., Tratner, I. & Verma, I. M. (1991) *Proc. Natl. Acad. Sci. USA* **88**, 5077–5081.
32. White, F. J., Hu, X.-T., Zhang, X.-F. & Wolf, M. E. (1995) *J. Pharmacol. Exp. Ther.* **273**, 445–454.
33. Hyman, S. E. (1996) *Neuron* **16**, 901–904.
34. Kreek, M. J. (1997) *Pharmacol. Biochem. Behav.* **57**, 551–569.
35. Shippenberg, T. S. & Rea, W. (1997) *Pharmacol. Biochem. Behav.* **57**, 449–455.
36. Chen, J. S., Zhang, Y. J., Kelz, M. B., Steffen, C., Ang, E. S., Zeng, L. & Nestler, E. J. (2000) *J. Neurosci.* **20**, 8965–8971.
37. Bibb, J. A., Chen, J. S., Taylor, J. R., Svenningsson, P., Nishi, A., Snyder, G. L., Yan, Z., Sagawa, Z. K., Nairn, A. C., Nestler, E. J., et al. (2001) *Nature (London)* **410**, 376–380.
38. Luscher, C., Nicoll, R. A., Malenka, R. C. & Muller, D. (2000) *Nat. Neurosci.* **3**, 545–550.
39. Malinow, R., Mainen, Z. F. & Hayashi, Y. (2000) *Curr. Opin. Neurobiol.* **10**, 352–357.
40. Scannevin, R. H. & Huganir, R. L. (2000) *Nat. Rev. Neurosci.* **1**, 133–141.
41. Robinson, T. E. & Kolb, B. (1999) (1997) *Eur. J. Neurosci.* **11**, 1598–1604.
42. Carey, M. & Smale, S. T. (2000) *Transcriptional Regulation in Eukaryotes* (Cold Spring Harbor Lab. Press, Plainview, NY).
43. Spencer, V. A. & Davie, J. R. (1999) *Gene* **240**, 1–12.